A New Era in HER2-Mutant Lung Cancer: Zongertinib Receives FDA Accelerated Approval

On August 8, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the oral tyrosine kinase inhibitor zongertinib (brand name Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, who have received prior systemic therapy.

🔍 Who Is Eligible?

Approximately 2–4% of patients with advanced non-small cell lung cancer (NSCLC) harbor mutations in the human epidermal growth factor receptor 2 (HER2). Until now, treatment options targeting HER2 have been extremely limited, with the only FDA-approved option being antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd; Enhertu). However, these therapies are not effective in all patients and carry significant risks of adverse effects, particularly complications such as interstitial lung disease.

In this context, the development of an effective and well-tolerated HER2-targeted therapy with the convenience of oral administration has become a major unmet need for both patients and oncologists.

This approval applies to adult patients who:

• Have unresectable or metastatic disease,
• Have received prior systemic therapy, such as platinum-based chemotherapy,
• Have not previously received a HER2-targeted tyrosine kinase inhibitor or antibody–drug conjugate (ADC).

The Oncomine Dx Target Test was also approved by the FDA as a companion diagnostic to identify patients eligible for treatment with zongertinib.

Zongertinib is an oral, next-generation tyrosine kinase inhibitor (TKI) that selectively targets HER2 mutations with high specificity. Unlike existing HER2 inhibitors, it has no activity against the epidermal growth factor receptor (EGFR), which helps reduce the incidence of common side effects such as skin rash and diarrhea.

📊 Beamion LUNG-1 Trial Efficacy Results

This approval is based on data from Beamion LUNG-1, an open-label, multi-center, multi-cohort clinical trial. The full study report was published on April 28, 2025, in the New England Journal of Medicine.

Primary endpoints: Objective Response Rate (ORR) and Duration of Response (DOR) (assessed by blinded independent central review per RECIST v1.1).

1️⃣ HER2-targeted treatment-naïve group

• Number of patients: 71
• ORR: 75% (95% CI: 63–83)
• DOR ≥6 months: 58%

2️⃣ Prior HER2-targeted ADC group

• Number of patients: 34
• ORR: 44% (95% CI: 29–61)
• DOR ≥6 months: 27%

💡 These results show that zongertinib is effective even in patients who did not respond to other HER2-targeted treatments.

⚠️ Safety and Warnings

The prescribing information for zongertinib includes warnings for the following risks:

• Hepatotoxicity
• Left ventricular dysfunction
• Interstitial lung disease / pneumonitis
• Embryo–fetal toxicity

💊 Recommended Dose

• <90 kg: 120 mg orally once daily
• ≥90 kg: 180 mg orally once daily

May be taken with or without food. Treatment continues until disease progression or unacceptable toxicity.

🩺 Why It Matters

• Provides an at-home oral option instead of intravenous infusions.
• Opens a new treatment avenue for patients progressing after platinum-based chemotherapy.
• Expands the therapeutic options in HER2-targeted lung cancer treatment.

📌 Conclusion: The FDA’s accelerated approval of zongertinib marks a significant milestone in the treatment of HER2-mutant NSCLC. With high response rates and the convenience of oral administration, it has the potential to change the treatment landscape for this patient population.